Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 3/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.80 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | VDR | P11473 | 1/20 | 0.78 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycoursodeoxycholic Acid SCHEMBL13851608 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL11962429 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL28793575 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL9151495 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL12917601 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycochenodeoxycholate SCHEMBL236354 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL59881 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL935341 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL10694925 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL1219678 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-20210148893-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2021-05-20 | — | — | US | claimed |
| EP-3423829-B1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| US-20210148893-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3423829-B1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-9989519-B1 | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) | Clayton Pharmaceuticals, LLC (US) | 2018-06-05 | — | — | US | disclosed |